Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Intensity Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +2 vs. Q4 2024
- Shares held
- 2.59M
- −114.3K (−4.2%) vs. Q4 2024
- Total value
- $5.10M
- +$339.2K (+7.1%) vs. Q4 2024
- New holders
- 3
- 8 more added
- Sold out
- 1
- 4 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INTS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $4.79M |
| Q1 2026 | 14 | $1.06M |
| Q4 2025 | 35 | $1.58M |
| Q3 2025 | 26 | $721.2K |
| Q2 2025 | 27 | $606.6K |
| Q1 2025 | 21 | $5.10M |
| Q4 2024 | 20 | $4.79M |
| Q3 2024 | 20 | $6.65M |
| Q2 2024 | 23 | $8.23M |
| Q1 2024 | 18 | $8.49M |
| Q4 2023 | 17 | $4.39M |
| Q3 2023 | 10 | $1.19M |
| Q2 2023 | 2 | $170.2K |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Intensity Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 15 | $30 | 0.00% | −2−11.8% | Reduced |
| Bank of America Corp | 63 | $124 | 0.00% | +13+26.0% | Added |
| Morgan Stanley | 500 | $985 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,376 | $4.68K | 0.00% | −272−10.3% | Reduced |
| UBS Group AG | 3,097 | $6.10K | 0.00% | +76+2.5% | Added |
| Stonebridge Financial Group, LLC | 9,525 | $18.8K | 0.00% | +1,224+14.7% | Added |
| Northern Trust Corp | 14,024 | $27.6K | 0.00% | +14,024 | New |
| State Street Corp | 14,500 | $28.6K | 0.00% | 00.0% | Unchanged |
| QTR Family Wealth, LLC | 17,420 | $34.3K | 0.03% | +17,420 | New |
| BlackRock, Inc. | 21,835 | $43.0K | 0.00% | −417−1.9% | Reduced |
| Citadel Advisors LLC | 25,801 | $50.8K | 0.00% | +10,837+72.4% | Added |
| Sentinus, LLC | 27,304 | $53.8K | 0.02% | +27,304 | New |
| One Charles Private Wealth Services, LLC | 31,800 | $62.6K | 0.02% | 00.0% | Unchanged |
| Blair William & Co | 37,805 | $74.5K | 0.00% | 00.0% | Unchanged |
| Mesirow Financial Investment Management, Inc. | 40,000 | $78.8K | 0.00% | +20,000+100.0% | Added |
| Sigma Planning Corp | 54,837 | $108.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 77,482 | $152.7K | 0.00% | +13,133+20.4% | Added |
| Brown Advisory Inc | 130,072 | $256.2K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 230,659 | $454.4K | 0.00% | +21,773+10.4% | Added |
| Armistice Capital, LLC | 872,547 | $1.72M | 0.05% | −254,321−22.6% | Reduced |
| Sapient Capital LLC | 976,797 | $1.92M | 0.04% | +33,956+3.6% | Added |
| GTS Securities LLC | 0 | $0 | 0.00% | −19,030−100.0% | Sold out |
| Lakeview Capital Partners, LLC | – | – | – | – | Not filed |